APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD. Revised January 2010 Page 1

Similar documents
WCG ACADEMY COURSE OVERVIEW

Human Research Protection Program Policy

RESEARCH ETHICS BOARD GUIDELINES SUBMISSION OF RESEARCH PROJECTS

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

11.0 FDA-Regulated Research Research Involving Investigational Drugs and Biologics

UC DAVIS OFFICE OF RESEARCH AAHRPP Preparation UC Davis Human Research Part III Investigator Manual. Cindy Gates IRB Administration

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

What is an IRB (Institutional Review Board)?

US Special Operations Command Human Research Protection Office

11.0 FDA-Regulated Research

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015

MARKEY CANCER CENTER STANDARD OPERATING PROCEDURES. SOP No.: MCC Type: Final

Investigational New Drug Development Steps for CRCs

Human Research Protection Program Policy

SOCIAL & BEHAVIORAL TEMPLATE WITH INSTRUCTIONS: 2.0 Background / Literature Review / Rationale for the study:

CHECKLIST: Pre-review

Learning about Clinical Trials

Protocol Submission Form

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

Human Research Protection Program Compliance Plan

The Role of the IRB in Clinical Trials: What Patients and Families Need to Know. Marjorie A. Speers, Ph.D. Executive Director, WCG Foundation

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

Rules of Human Experimentation

ELEMENTS OF A DATA MONITORING PLAN

TITLE: DF/HCC Investigator-Sponsored Multi-Center Research POLICY #: MULTI-100 Page: 1 of 4 Effective Date: 1/31/19

Recruitment of Research Participants

3.1. Overall Principal Investigator (PI), who holds the IDE and/or is the Sponsor

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST

APPLICATION FORM. Application for a Recognised Research Ethics Committee (REC) Opinion on a Clinical Trial on a Medicinal Product for Human Use.

1 The Clinical Research Coordinator (CRC)... 1

CANCER CENTER SCIENTIFIC REVIEW COMMITTEE

Regulatory Documentation and Submissions for C2012 Clinical Trials DCP SOP #1

1. POLICY STATEMENT: 2. BACKGROUND:

Investigator Manual. Human Subjects Protection Program

TOP 10 INVESTIGATOR RESPONSIBILITIES WHEN CONDUCTING HUMAN SUBJECTS RESEARCH

Office for Human Subject Protection. University of Rochester

UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE INSTITUTIONAL REVIEW BOARD CONFLICTS OF INTEREST

University of California, Irvine Human Research Protections Standard Operating Policies and Procedures

BACKGROUND PURPOSE 9/24/2009 DATA AND SAFETY MONITORING

VCU Faculty Held IND and IDE Procedure Handbook

PROTOCOL DRAFTING GUIDE

Human Research Protection Program. Investigator Manual

I. Purpose. II. Definitions. Last Approval Date

ROLE OF THE RESEARCH COORDINATOR Investigational New Drug Application-Sponsor Responsibilities 21CFR Part , subpart D

Device research sponsors, whether companies or investigators, are held responsible for meeting the same regulations.

Indiana University, Purdue University Indianapolis Institutional Biosafety Committee (IBC) Policy & Procedure Manual.

Human Subjects Protection: Training for Research Teams

Clinical Trials Management for Molecular Diagnostics. April 2016

European Social Survey European Research Infrastructure Consortium (ESS ERIC) Research Ethics Committee Terms of Reference.

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management

USE OF INVESTIGATIONAL DRUGS OR BIOLOGICS IN HUMAN SUBJECTS RESEARCH

POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)

Clinical Trial Basics:

HUMANITARIAN USE DEVICES 3/8/2016

EIGHT BASIC ELEMENTS OF INFORMED CONSENT

Guidance on Requirements of the Sponsor and the Investigator as a Sponsor

RESEARCH ASSOCIATE (RA), SENIOR RESEARCH ASSOCIATE (SRA)

CONTACT INFORMATION. PHRC Office. Josephine O Driscoll-Davis. Michael Ducey

Human Research Protection Program Plan

External IRB Review What Does it Mean for Your Institution

DATED: 25/05/2018 GDPR PRIVACY NOTICE FOR HOPES & DREAMS LTD FOR EMPLOYEES, CHILDREN ATTENDING A GROUP NURSERY AND THEIR PARENTS

1.0 INTRODUCTION AND OVERVIEW

INVESTIGATIONAL DEVICE EXEMPTION APPLICATION. IDE Title (if title being used)

Top Ten Investigator Responsibilities When Conducting Human Subjects Research

DANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR CLINICAL RESEARCH

Demystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?

Ethical Principles in Clinical Research. Disclaimer. Christine Grady Department of Bioethics NIH Clinical Center

THE UNIVERSITY OF HOUSTON IACUC POLICY

Flexible Working Policy

ROLE OF THE RESEARCH COORDINATOR Study Startup Best Practices May 2016

Child and Family Agency. Research Ethics Committee Guidelines

Views of a Clinical Study Report

Sponsor-Investigator Responsibilities In Clinical Trials

Presented by NC TraCS Institute UNC Office of Clinical Trials UNC Network for Research Professionals

RECRUITING OF AND ADVERTISING FOR SUBJECTS

CLINICAL AND TRANSLATIONAL RESEARCH COMMITTEE SUBMISSION APPLICATION

Regulatory and ethical requirements in medical device studies. Finland

INVESTIGATOR HANDBOOK

RSC/CT Det. no. 1/2013

TITLE: DF/HCC Investigator-Sponsored Multi-Center TrialsResearch POLICY #: MULTI-100 Page: 11 of 54 Effective Date: 8/31/17 1.

Regulatory Binder: Set-up and Maintenance

DARTMOUTH COLLEGE BIOLOGICAL SAFETY PROGRAM Institutional Biosafety Committee Subcommittee for Clinical Gene Transfer

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework

ORC Sponsor-Investigator IDE Checklist

Isidro B. Salusky, MD

FDA Sponsor and Investigator Responsibility Checklist

R&D Administration Manager. Research and Development. Research and Development

IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES

Clinical trial information leaflet and consent

Ethical Principles in Clinical Research

Institutional Review Board Compliance Elizabeth City State University

RESEARCH AUDIT Standard Operating Procedure

Cancer Center Clinical Trials Office

4.2. Investigator Regulatory Binder: Files, usually a binder, maintained by the investigator at the investigative site.

1 Purpose. 2 Procedure. Title: FDA-Regulated Research. SOP Number: 1301 Effective Date: June 2, Previous Version Dates:

Compliance and Quality Monitoring: What, Why, When, and How

Recruitment of Subjects Best Practices

MARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: MCCCRO-P

SUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES

Investigator Manual Revised August 19, 2013

Transcription:

APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD Revised January 2010 Page 1

The IRB Proposal Includes: 1. All documents, other than the informed consent form, should be understandable to an informed lay-person (ie, the non-clinician/non-scientist members of the board should be able to understand the documents without reference to outside assistance). 2. A brief (10 page maximum, 12 pt. Times New Roman, 1 margins) description of the scientific background, and merits, of the proposal project. 3. A full description of all research procedures and devices, providing reference to the literature when appropriate. 4. A full reference bibliography. 5. A brief CV (2 page maximum) for each major research participant in the study. The CV should clearly outline the expertise this person brings to the project, and the qualifications of this person to perform any specialized task. 6. If applicable, an Informed Consent form that summarizes the research purposes and procedures in simple language (6 th grade reading level). 7. If applicable, a HIPAA Research Authorization form that authorizes the use and disclosure of protected health information. 8. If applicable, any text for subject recruitment/advertising. (e.g. brochures, flyers, radio ads, etc.) Revised January 2010 Page 2

The Researcher s responsibility includes: 1. Providing a written annual report of research progress, and/or a final report. The annual report constitutes an application for a one-year extension of the research application. The report must include 2 copies of recent subject consent forms, a description of any adverse subject reactions that may have occurred during the study period, and the actions you took to address those reactions. 2. Depending upon the nature of the research project, and its potential hazards or benefits, the IRB may require reports on a more frequent basis. 3. Prompt notification of any change in research methods, procedures, and key personnel. This notification must be accompanied by an appropriately revised IRB application and IRB Amendment Form. 4. Prompt notification about subjects that reacted negatively to the research procedure. Not every adverse reaction needs to be reported immediately, only the severe or unexpected ones. As a general guideline, you should report to the IRB (A) Anytime a subject has a strong negative reaction to the research procedure, whether or not this type of reaction was listed as a potential negative side effect in the informed consent form. A strong negative reaction includes anything which causes a reasonable concern about the health and welfare of the subject. (B) Anytime a subject specifically contacts you about a negative reaction to the research procedure (no matter how minor this reaction may seem). (C) Anytime a subject exhibits a negative reaction that was not documented as a possible side effect in the original IRB proposal. 5. The researcher must allow the subject a minimum of 24 hours to read, and review, the informed consent form before data collection begins. The requirement will be waived only when the IRB is convinced that it would seriously undermine the goals of the research project without creating unacceptable risk for the subjects. 6. The researcher must keep all consent forms on file, and available for inspection, for a period of a least three years from the date of the last data collection. 7. The researcher must make all current research results available for inspection by the IRB, or its appointed representatives, while data is being collected. 8. The researcher must allow on site inspection of the laboratory, data, and data collection procedures by the IRB, or its appointed representatives. *This document will be sent to the Investigator when his/her protocol has been approved. A copy must be signed by the investigator and returned to the Research Office.* Revised January 2010 Page 3

INSTRUCTIONS FOR SUBMITTING A PROTOCOL TO THE INSTITUTIONAL REVIEW BOARD (IRB) FULL REVIEW 1. Complete the attached GENERAL INFORMATION SHEET. This form must be typed. The space on the top of the page is for IRB use only. The IRB number will be assigned upon submission of the application. 2. Prepare a description of the research protocol by answering the questions which are listed on the attached RESEARCH DESCRIPTION INSTRUCTIONS SHEET. Each response should be numbered to correspond with the applicable question. PLEASE NOTE: THE RESEARCH DESCRIPTION SHOULD NOT EXCEED 10 PAGES, WITH 1 MARGINS, 12 PT. TIMES NEW ROMAN FONT 3. Read carefully the INSTRUCTIONS FOR DOCUMENTATION OF INFORMED CONSENT. Using the sample format, submit the consent form that you propose to use. 4. If the research is part of a National Institutes of Health (NIH) MULTICENTER CLINICAL TRIAL, NIH requires that the local IRB receive a copy of the NIH-approved sample informed consent document. Any deletion or substantive modification of information concerning risks or alternative procedures contained in the sample informed consent document must be justified in writing by the investigator and approved by the IRB. For trials sponsored by the National Cancer Institute (NCI), investigators must forward copies of such IRB-approved changes, with their justifications, to the appropriate Cooperative Group headquarters. The NIH-approved consent document and any justification for changes in the Risks and/or Alternatives sections should be submitted as part of the application packet. 5. If your research project involves subjects under the age of 18, read carefully the DESCRIPTION OF REQUIREMENTS FOR RESEARCH INVOLVING CHILDREN which is attached. If appropriate, submit the assent form that you propose to use. (Please remember that this document should be written in language easily understood by children.) 6. If the research project involves the use of approved drugs, investigational new drug(s) or an approved drug for an unapproved use, complete the DRUG INFORMATION FORM. 7. If the research project involves the use of investigational new device(s), complete the DEVICE INFORMATION FORM. 8. If the research project involves the use of radioactive materials, complete the RADIATION SAFETY INFORMATION FORM. 9. If prisoners are to be included as subjects in the research project, notify a Research Subjects Office staff member. The federal regulations have special membership requirements with which the IRB must comply when reviewing research involving prisoners. 10. If subjects from other organizations external to New York Chiropractic College are to be recruited for the study, written approval should be obtained from an authorized official of that institution. (A statement of any preliminary contacts with the appropriate officials should be attached to the materials submitted for review.) 11. If the research project is to be submitted to either an external or internal funding source, two copies of the grant, contract proposal, or device protocol should be submitted to the IRB OR if the research involves the administration of drugs, three copies of the detailed drug research protocol and three copies of the physician s brochure (if applicable) must be submitted to the IRB. 12. If the research includes survey or interview procedures, the questionnaire, interview questions or assessment scales must be included in the application. (NOTE: If standardized scales and/or questionnaires are to be used, submit two copies to the IRB.) 13. Obtain the appropriate signatures as specified on the SIGNATURE ASSURANCE SHEET. If the principal investigator is also the director of the department, the dean or equivalent should review and sign the signature assurance sheet. 14. Before submitting the research protocol application to the IRB, the requested information MUST BE COLLATED in the following order: a. General Information Sheet b. Research Description Summary c. Informed Consent Form d. NIH-Approved Sample Informed Consent Document, if applicable e. Assent Form, if applicable Revised January 2010 Page 4

f. Instrument to be used for data collection, if applicable (e.g., questionnaire, interview questions or assessment scales) g. Drug Information Form, if applicable h. Device Information Form, if applicable i. Radiation Safety Form, if applicable j. Signature Assurance Sheet k. HIPAA Research Authorization Form, if applicable 15. Submit the following collated materials to the Research Department Office. a. 2 (two) copies of the IRB Research Protocol (See #14 above for a description of items to be included in the Research Protocol. Note that in an effort to decrease the number of pages, the investigator is encouraged to submit two-sided copies, if at all possible.) b. 2 (two) copies of the grant, contract, or device proposal, if the protocol does not involve administration of drugs c. 3 (three) copies of the detailed drug protocol and physician s brochure, if the protocol involves administration of drugs. d. 1 (one) Electronic version sent to the IRB administrative assistant (asimolo@nycc.edu) Please note that the IRB meets on a monthly basis. Protocols should be submitted two weeks before a scheduled IRB meeting. Protocols are assigned on a first come, first served basis and will be placed on the next available agenda. You are encouraged to submit your protocol as early as possible. Investigators are encouraged to submit their applications by NOON on the submission deadline. Full reviews require that the Principal Investigator (PI), or a representative knowledgeable in the protocol, attend the meeting at which the application is reviewed. A review date will be assigned to the protocol at the time of submission. If the PI is not available on this date, this should be made clear to staff of the Research Subjects Office at the time of submission. Note that incomplete IRB applications will not be scheduled for review but returned to the PI. If you have questions concerning submission of a research protocol for IRB review, please call the Research Department Office at (315) 568-3868. Revised January 2010 Page 5

INSTRUCTIONS FOR DOCUMENTATION OF INFORMED CONSENT Informed consent is one of the primary ethical considerations underlying research with human subjects. It is too often forgotten that informed consent is an ongoing educational process that takes place between the investigator and prospective subject; it is not just a piece of paper that must be signed. Nevertheless, in most cases the federal regulations require that informed consent be documented. It should be reiterated, however, that the consent document does not substitute for discussion or subjects education. Below are instructions for preparing the written consent form. Please follow the instructions carefully. 1. Use the standardized consent form in your application packet. Items with asterisks may be deleted if not applicable 2. The language in the form should be aimed at a sixth-grade reading level. Do not use medical or technical jargon. 3. In addition to the information included on the standardized form, when appropriate, one or more of the following items should be included on the consent form: a. Anticipated circumstances under which the subjects PARTICIPATION may be TERMINATED by the investigator without regard to the subject s consent. b. The CONSEQUENCES of a subject s decision to WITHDRAW from the research, and procedures for orderly termination of participation by the subject. c. The APPROXIMATE NUMBER OF SUBJECTS involved in the study 4. If the RESEARCH INVOLVES THE PARTICIPATION OF MINORS (under 18 years of age), please read the Description of Requirements for Research Involving Children. Additional requirements concerning the parental consent forms and children assent forms are discussed. 5. If the RESEARCH ACTIVITIES ARE DIRECTED TOWARD PREGNANT WOMEN, both the mother and father must give consent after having been fully informed regarding the impact of the research on the fetus. (NOTE: the federal regulations do specify certain conditions under which the father s consent is not necessary. For a list of those conditions contact the Research Department.) 6. If the RESEARCH COULD POSSIBLY PUT AT RISK (1) AN UNBORN CHILD, (2) A MAN OR WOMAN S ABILITY TO PROCREATE, (3) A WOMAN S ABILITY TO CONCEIVE OR CARRY A CHILD, the following statement(s) (revised to meet the needs or your particular study) should be included in the consent form. a. If I am pregnant, I cannot participate in this study. If I am a woman who could have children, it will be necessary to have a urine (or serum) test to see if I am pregnant before I start this study. If I am a sexually-active male or female, I agree to take precautions to avoid the possibility of impregnation because it is not known how this drug (treatment, device, etc.) will affect an unborn child. If I am a woman and become pregnant during the course of this study, I will notify the principal investigator of this fact as soon as possible. 7. If the research is part of an NIH-sponsored multicenter clinical trial, a copy of the NIH-approved sample informed consent document must be included in the application packet. 8. For research involving HIV screening and/or AIDS research, there are additional IRB requirements for designing and implementing the research and for obtaining informed consent. Contact the Research Office at (315) 568-3868. Revised January 2010 Page 6